News headlines about Adamas Pharmaceuticals (NASDAQ:ADMS) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamas Pharmaceuticals earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 44.9615107951644 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern’s rankings:

Adamas Pharmaceuticals (NASDAQ:ADMS) traded down 0.8180% on Tuesday, hitting $20.6001. The stock had a trading volume of 293,190 shares. Adamas Pharmaceuticals has a 52-week low of $12.10 and a 52-week high of $22.58. The company’s market cap is $463.79 million. The firm’s 50-day moving average is $17.59 and its 200-day moving average is $17.06.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.81) by ($0.12). Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter in the prior year, the business earned ($0.78) earnings per share. The company’s quarterly revenue was down 90.9% on a year-over-year basis. Equities research analysts anticipate that Adamas Pharmaceuticals will post ($3.79) earnings per share for the current fiscal year.

Several brokerages have weighed in on ADMS. Mizuho reiterated a “buy” rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, September 5th. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Piper Jaffray Companies reiterated an “overweight” rating and issued a $30.00 target price on shares of Adamas Pharmaceuticals in a report on Friday, September 1st. They noted that the move was a valuation call. William Blair reiterated an “ourperform” rating on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Finally, JMP Securities reiterated an “outperform” rating and issued a $33.00 target price (up from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $32.00.

TRADEMARK VIOLATION WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/12/adamas-pharmaceuticals-adms-earns-news-impact-rating-of-0-23.html.

In related news, major shareholder Great Point Partners Llc sold 380,000 shares of Adamas Pharmaceuticals stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $17.08, for a total value of $6,490,400.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is currently owned by company insiders.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Insider Buying and Selling by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.